Novo Nordisk Faces Dual Challenges Amid Strategic Shifts
26.01.2026 - 13:13:04 | boerse-global.de
The Danish pharmaceutical giant Novo Nordisk is navigating a complex period marked by operational restructuring and legal scrutiny. As the company advances the U.S. launch of its oral Wegovy tablet, it confronts new job cuts and a significant antitrust lawsuit related to its diabetes portfolio.
A new legal challenge emerged last Friday when a class-action lawsuit was filed against Novo Nordisk in a U.S. federal court in New York. The complaint alleges anticompetitive practices concerning the diabetes drug Victoza.
Plaintiffs accuse Novo Nordisk and Teva Pharmaceuticals of engaging in a “pay-for-delay” agreement. This alleged deal purportedly pushed back the market entry of more affordable generic versions until Read more...
So schätzen die Börsenprofis Novo Aktien ein!
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
DK0062498333 | NOVO | boerse | 68521237 |
